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Background: Chronic obstructive pulmonary disease, COPD, is an increasing cause of morbidity and mortality
worldwide, and an imbalance between proteases and antiproteases has been implicated to play a role in COPD
pathogenesis. Matrix metalloproteinases (MMP) are important proteases that along with their inhibitors, tissue
inhibitors of metalloproteinases (TIMP), affect homeostasis of elastin and collagen, of importance for the structural
integrity of human airways. Small observational studies indicate that these biomarkers are involved in the pathogenesis
of COPD. The aim of this study was to investigate serum levels of MMP-9 and TIMP-1 in a large Swedish population-
based cohort, and their association with disease severity and important clinical symptoms of COPD such as productive
cough.
Methods: Spirometry was performed and peripheral blood samples were collected in a populations-based cohort
(median age 67 years) comprising subjects with COPD (n = 594) and without COPD (n = 948), in total 1542 individuals.
Serum MMP-9 and TIMP-1 concentrations were measured with enzyme linked immunosorbant assay (ELISA) and related
to lung function data and symptoms.
Results: Median serum MMP-9 values were significantly higher in COPD compared with non-COPD 535 vs. 505 ng/ml
(P = 0.017), without any significant differences in serum TIMP-1-levels or MMP-9/TIMP-1-ratio. In univariate analysis,
productive cough and decreasing FEV1% predicted correlated significantly with increased MMP-9 among subjects with
COPD (P = 0.004 and P = 0.001 respectively), and FEV1% predicted remained significantly associated to MMP-9 in a
multivariate model adjusting for age, sex, pack years and productive cough (P = 0.033).
Conclusion: Productive cough and decreasing FEV1 were each associated with MMP-9 in COPD, and decreasing FEV1
remained significantly associated with MMP-9 also after adjustment for common confounders in this population-based
COPD cohort. The increased serum MMP-9 concentrations in COPD indicate an enhanced proteolytic activity that is
related to disease severity, and further longitudinal studies are important for the understanding of MMP-9 in relation to
the disease process and the pathogenesis of different COPD phenotypes.
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Chronic obstructive pulmonary disease, COPD, is a
common chronic disease, characterised by chronic air-
flow limitation, recurring exacerbations and a range of
pathologic changes in the lungs. COPD is described as a
heterogeneous syndrome of overlapping conditions such
as chronic bronchitis, emphysema and bronchiolitis [1].
Recent studies and guidelines acknowledge the import-
ance of airway inflammation in the process of COPD de-
velopment [1]. The chronic inflammatory processes in
COPD leads to the loss of alveolar attachments to the
small airways and decreased lung elastic recoil [2]. In
turn, these changes diminish the ability of the airways to
remain open during expiration, thus limiting expiratory
flow.
Current hypotheses suggest that inflammation, protease-
antiprotease imbalance, oxidative stress and accelerated
ageing of the lung can be accredited to the pathogen-
esis of COPD [3]. As part of the protease-antiprotease
system, matrix metalloproteinase-9 (MMP-9) has gained
an increasing research interest in COPD [4]. MMP-9 is a
multi-domain enzyme with many functions in biology and
pathology, among which the breakdown of collagen and
gelatine is of significance in the pathogenesis of COPD
[5-7]. Finding a COPD biomarker easily measured in per-
ipheral blood, is clearly an appealing goal, especially if this
biomarker would correlate with measures of disease
progression.
In a study of resected human lung parenchyma from
26 patients, MMP-9 expression and the molar ratio of
MMP-9 to tissue inhibitor of metalloproteinases-1
(TIMP-1) were increased in smokers compared with
non-smokers, and correlated with the burden of
cigarette smoking. There was also an inverse association
between MMP-9 concentrations and FEV1% predicted
values [8]. In a Swedish population-based study employ-
ing 1,016 subjects aged 70 years, the serum levels of
MMP-9 were inversely associated with FEV1 without
discriminating for obstructive lung function impairment.
MMP-9 and TIMP-1 serum levels were also associated
with smoking status, being lowest in never-smokers and
highest in current smokers [9].
MMP-9 is also thought to play an important role in
lung remodelling and has been investigated as a poten-
tial biomarker of COPD, given that increased elastolytic
activity is a significant part of emphysema [10]. In a
study comparing 23 patients with moderate to severe
COPD with age-matched controls, serum MMP-9 was
negatively correlated with both FEV1 and the FEV1/FVC
ratio [10]. TIMP-1 is also important to consider when
studying MMP-9, since it is suggested to inhibit the elas-
tolytic activity of MMPs [11,12]. The relationship be-
tween these biomarkers and FEV1 among subjects with
COPD has so far only been evaluated in fairly smallobservational studies, resulting in important information
regarding the involvement of metalloproteinases in the
pathogenesis of COPD. Besides lung function, also bron-
chitis symptoms and exacerbations are negative prognos-
tic factors and related to disease severity in COPD [13,14],
hence important to evaluate in relation to these bio-
markers. However, there is a significant under-diagnosis of
COPD [15-17] and studies of population-based cohorts
are therefor important in order to evaluate the significance
of these biomarkers in COPD pathogenesis in general.
The aim of this population-based study was to com-
pare serum MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio
in subjects with and without COPD and further to
evaluate the association between these biomarkers and
factors of clinical significance, such as burden of tobacco
smoking, productive cough and lung function among
subjects with and without COPD. The hypothesis was
that the study setup with COPD subjects and non-
COPD subjects as controls would elucidate whether
MMP-9 is related to COPD severity in a population
based study.Methods
Participants and design
After re-examination of four adult population cohorts
from the OLIN-studies (Obstructive Lung Disease in
Northern Sweden) during 2002–04, all subjects with
COPD were identified together with age and gender-
matched controls without obstructive lung function im-
pairment. Since 2005, the study population (n = 1986) has
been annually invited to a basic examination program in-
cluding spirometry and a structured interview [18].
This report is based on data from the examinations in
2005, when blood samples were collected in addition to
the basic program. In 2005, 1806 out of 1915 subjects
still alive (94%) participated, whereof 164 subjects not
able to attend the examinations were interviewed by
telephone, 1626 subjects performed spirometry and 1621
participated in the blood sampling. The study population
in this paper includes all subjects with complete data
from both spirometry and blood samples (n = 1542). The
Regional Ethics Committee at Umeå University approved
the study, which was carried out according to the declar-
ation of Helsinki.Questionnaire
Previously well validated questions regarding respiratory
symptoms were used in a structured interview [19-21].
The Modified Medical Research Council Dyspnoea
Scale, mMRC, was included in the questionnaire to
grade dyspnoea, scale 0–4 [22]. In addition, data on
smoking habits and co-morbidities were included.
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Body Mass Index (BMI) was calculated: weight (kg)/
(height (m)*height (m)) and was classified as under-
weight (<20), normal (20– < 25), overweight (25– < 30)
and obesity (≥30).
Smoking habits were classified as: non-smokers, ex-
smokers (stopped since at least one year) and current
smokers. Pack-years were calculated as (number of ciga-
rettes smoked per day × number of years smoked)/20.
We defined productive cough as cough and phlegm on
most days for at least three months during the last
12 months. Clinically significant dyspnoea was defined
as mMRC score ≥2.
Spirometry and classification of COPD
The lung function tests were performed using a dry
spirometer, Mijnhardt Vicatest 5, the Netherlands, fol-
lowing the ATS guidelines [23]. A reversibility test was
performed if FEV1/highest of FVC or SVC <0.70, or if
FEV1 < 80% of predicted value. COPD was defined as
FEV1 divided by FVC or SVC <0.70, using the highest
value pre- or post bronchodilatation. Disease severity
was classified according to the GOLD (Global Initiative
for Obstructive Lung Disease) spirometric criteria
based on FEV1% predicted; GOLD 1 – 4 [1]. Swedish
spirometric reference values were used [24].
Laboratory analysis
All samples were stored since 2005 at −20°C, thereafter
thawed and analysed at the same time. Serum concen-
trations of MMP-9 and TIMP-1 were assayed using the
same batch of a commercially available ELISA kit
(DuoSet® ELISA Development System, R&D Systems
Europe Ltd., United Kingdom) according to the manu-
facturer’s instructions. Briefly, recombinant human
MMP-9 and TIMP-1 were used to construct a standard
curve (range 39–2,500 pg/ml) for each set of samples
assayed, serum samples were diluted 150 times and
concentration read from the standard curve were
multiplied by the dilution factor.
Statistical analysis
Dichotomous variables were analysed using Pearson’s χ2,
continuous variables with the independent variable t-test
for variables that met the assumption of normal distri-
bution, and the non-parametric Mann–Whitney U-test
for those that did not. Non-normal distributed data are
presented as median and interquartile range (IQR). Since
there were very few subjects in GOLD 3 and 4, they
were treated as one group. Univariate analyses of bio-
markers (MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio),
stratified by COPD and non-COPD, were performed in
relation to factors as sex, age, BMI-class, smoking habits,
pack years, productive cough and FEV1% predicted. Thesame biomarkers were analysed in linear regression
models, stratified by COPD and non-COPD, including
the independent variables sex, age, pack years, product-
ive cough and FEV1% predicted. The Statistical Package
for the Social Sciences (SPSS) version 21.0 for Mac was
used for all analyses and P-values < 0.05 were considered
significant.Results
Study population
The basic characteristics of the study population (COPD
n = 594, non-COPD n = 948) are presented in Table 1.
There were significant differences observed in distribu-
tion of sex, age and BMI when comparing COPD and
non-COPD.Biomarkers in non-COPD and COPD as well as COPD by
GOLD stage
Median serum MMP-9 values were significantly higher in
COPD compared with non-COPD, 535 ng/ml vs. 505 ng/ml
(p = 0.017), whereas there were no significant differ-
ences in serum TIMP-1-levels or MMP-9/TIMP-1-ratio
(Table 1). There was a tendency towards higher MMP-
9-levels with higher GOLD-stage (Table 1). Figure 1
shows the association between MMP-9 values and
FEV1% predicted in COPD by GOLD stage, each circle
representing one subject, whereas Figure 2 shows the
association between MMP-9/TIMP-1-ratio and FEV1%
predicted in COPD by GOLD stage.Univariate association with biomarkers in non-COPD and
COPD
In univariate analysis, pack years and current smoking
were significantly associated with increased MMP-9 in
both non-COPD and COPD. In COPD, productive
cough and decreasing FEV1% predicted were signifi-
cantly associated with increased MMP-9 (Table 2).
Corresponding analyses for TIMP-1 showed that in-
creasing age was significantly related to increasing TIMP-
1 in both non-COPD and COPD (Beta: 0.122, p < 0.001
and 0.108, p = 0.009 respectively). Increasing pack years
was associated with decreasing TIMP-1 in non-
COPD(Beta: −0.074, p = 0.023), while current smoking
was associated with decreased TIMP-1 in COPD (Beta:
−0.123, p = 0.013). Overweight was associated with in-
creased TIMP-1 only in COPD (Beta: 0.113, p = 0.014).
Increasing pack years and current smoking were asso-
ciated with increasing MMP-9/TIMP-1-ratio in both
non-COPD and COPD. In non-COPD increasing age
was associated with a decreasing MMP-9/TIMP-1-ratio,
while in COPD, overweight and decreasing FEV1% pre-
dicted were associated with increasing ratio (Table 3).
Table 1 Study population characteristics; demographics, smoking habits, respiratory symptoms and biomarker levels,
comparing non-COPD and COPD and also presented by GOLD stages
Non-COPD COPD P-value GOLD 1 GOLD 2 GOLD 3-4
(n = 948) (n = 594) (n = 378) (n = 190) (n = 26)
Female, n (%) 447 (47) 248 (42) 0.038 155 (41) 87 (46) 6 (23)
Age (years), median (IQR) 67 (55–71) 69 (57–71) 0.015 69 (56–71) 69 (58–71) 70 (64–79)
BMI (kg/m2), median (IQR) 26.8 (24.3-29.7) 26.1 (23.5-28.7) <0.001 25.8 (23.6-28.4) 26.5 (23.5-29.0) 27.6 (21.7-29.4)
Pack years, median (IQR) 0.8 (0–12) 14 (0–27) <0.001 8.6 (0–24) 18.5 (2.0-32.3) 26.9 (14.8-42.5)
Non-smoker, n (%) 443 (47) 149 (25) <0.001 113 (30) 34 (18) 2 (8)
Ex smoker, n (%) 384 (41) 247 (42) 0.676 153 (40) 75 (41) 19 (73)
Current smoker, n (%) 120 (13) 197 (33) <0.001 111 (29) 81 (43) 5 (19)
Productive cough, n (%) 212 (22) 238 (40) <0.001 125 (33) 93 (49) 20 (77)
mMRC dyspnoea score ≥2, n (%) 46 (5) 75 (13) <0.001 17 (5) 40 (22) 18 (69)
FEV1% predicted
†, median (IQR) 1.03 (0.93-1.13) 0.85 (0.73-0.96) <0.001 0.93 (0.86-1.01) 0.70 (0.64-0.75) 0.44 (0.37-0.47)
MMP-9 (ng/ml), median (IQR) 505 (364–606) 535 (315–653) 0.017 513 (241–626) 559 (379–662) 647 (565–692)
TIMP-1 (ng/ml), median (IQR) 316 (229–490) 304 (227–439) 0.252 311 (237–467) 294 (218–425) 298 (247–383)
Ratio of MMP-9/TIMP-1, median (IQR) 1.36 (0.85-2.09) 1.5 (0.83-2.32) 0.168 1.46 (0.78-2.18) 1.48 (0.9-2.5) 1.95 (1.47-2.79)
IQR = Inter quartile range. Significant p-values, p < 0.050, in bold.
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and COPD
In the multivariate analyses stratified by non-COPD and
COPD, MMP-9 remained significantly associated with
increasing pack-years in non-COPD and decreasing
FEV1% predicted in COPD, independent of sex, age and
productive cough (Table 4). In a corresponding model,
TIMP-1 was associated with increasing age in both















Figure 1 Association between FEV1% predicted and MMP-9 in COPD
and FEV1% predicted in each GOLD stage with the R
2 value indicatingp = 0.014), while in non-COPD only associated with
productive cough and decreasing pack years (Beta:
0.065, p = 0.050 and −0.072, p = 0.034 respectively).
Similar analyses of the MMP-9/TIMP-1 ratio revealed a
significant association with increasing pack years in
both non-COPD and COPD, while the association with
increasing age was border-line significant in non-
COPD (p = 0.051) as was decreasing FEV1% predicted









1: R2 Linear = 8,415E-4
2: R2 Linear = 0,004
3-4: R2 Linear = 0,046
subjects, the lines show the linear association between MMP-9
the strength of the association.






















1: R2 Linear = 0,007
2: R2 Linear = 9,756E-4
3-4: R2 Linear = 6,371E-6
Figure 2 Association between FEV1% predicted and the MMP-9/TIMP-1-ratio in COPD subjects, the lines show the linear association
between MMP-9/TIMP-1-ratio and FEV1% predicted in each GOLD stage with the R
2 value indicating the strength of the association.
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infection, cancer diagnosis and oral corticosteroid use
did not alter main findings of the multivariate analyses.
Discussion
In this population-based study, subjects with COPD had
significantly higher serum MMP-9 compared to those
without obstructive lung function impairment. Among
subjects with COPD, MMP-9 was significantly associated
with productive cough and decreasing FEV1% predicted,Table 2 Univariate analyses of associations between
various factors and MMP-9 in non-COPD and COPD,
respectively
Non-COPD COPD
Beta P-value Beta P-value
Sex (female†) −0.050 0.122 −0.070 0.087
Age‡ 0.003 0.928 0.037 0.370
Underweight (normal weight†) 0.038 0.512 −0.039 0.560
Overweight (normal weight†) −0.018 0.634 −0.051 0.266
Obese (normal weight†) 0.064 0.155 0.022 0.706
Pack years‡ 0.096 0.003 0.115 0.005
Ex-smoker (non smoker†) −0.011 0.744 0.098 0.052
Current smoker (non smoker†) 0.118 0.005 0.218 <0.001
Productive cough, prc (no prc†) 0.040 0.215 0.119 0.004
mMRC≥ 2 (<2†) 0.029 0.377 0.049 0.238
FEV1% pred
‡ −0.060 0.067 −0.131 0.001
†reference value, ‡continuous variable. Significant p-values, p < 0.050, in bold.and in a multivariate model, decreasing FEV1 remained
significantly associated with MMP-9, independent of
sex, age, pack years and productive cough. In corre-
sponding analyses among non-COPD-subjects only pack
years remained significantly associated with MMP-9.
Serum TIMP-1 levels were similar in COPD and non-
COPD, however, analysis of the MMP-9/TIMP-1-ratio
may suggest an imbalance in the pulmonary protease-
antiprotease homeostasis among COPD-subject, with a
predominance of proteolytic activity.Table 3 Univariate analyses of associations between
various factors and MMP-9/TIMP-1 ratio in non-COPD and
COPD, respectively
Non-COPD COPD
Beta P-value Beta P-value
Sex (female†) −0.038 0.245 −0.007 0.874
Age‡ −0.081 0.012 −0.074 0.072
Underweight (normal weight†) 0.001 0.992 −0.054 0.423
Overweight (normal weight†) −0.124 0.221 −0.118 0.010
Obese (normal weight†) −0.009 0.837 0.202 0.840
Pack years‡ 0.099 0.002 0.124 0.003
Ex-smoker (non smoker†) 0.045 0.195 0.102 0.043
Current smoker (non smoker†) 0.106 0.011 0.256 <0.001
Productive cough, prc (no prc†) 0.004 0.904 0.060 0.148
mMRC≥ 2 (<2†) 0.003 0.929 0.034 0.424
FEV1% pred
‡ −0.040 0.219 −0.118 0.004
†reference value, ‡continuous variable. Significant p-values, p < 0.050, in bold.
Table 4 Multivariate analyses of factors associated with
MMP-9 in in non-COPD and COPD, respectively
Non-COPD COPD
Beta P-value Beta P-value
Sex (female†) 0.038 0.256 0.060 0.140
Age‡ 0.025 0.460 0.032 0.444
Productive cough (no prc†) 0.012 0.714 0.078 0.068
Pack years‡ 0.084 0.013 0.077 0.069
FEV1% pred
‡ −0.052 0.120 −0.092 0.033
†reference value, ‡continuous variable. Significant p-values, p < 0.050, in bold.
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shown previously [8,9,25]. In the present univariate ana-
lyses, current smoking was associated with MMP-9 as
well as increased MMP-9/TIMP-1 ratio, suggesting that
smoking per se increases the proteolytic activity in both
COPD and non-COPD. In this context, it deserves to be
mentioned that the effect of smoking on MMP-9 may, at
least in sputum, remain at least 6 months after smoking
cessation [26]. Furthermore, the burden of tobacco
smoke exposure, assessed as pack years, was associated
with increasing MMP-9/TIMP-1-ratio in both COPD
and non-COPD, indicating a tobacco smoke-induced in-
crease in proteolytic activity, independent of sex, age
and FEV1. According to a recently published study of 80
women with COPD and 40 controls, not only smoking,
but also exposure to biomass combustion, was related to
differences in metalloproteinases, including increased
MMP-9 and MMP-9/TIMP-1 ratio, among those with
COPD [27].
Small observational studies have demonstrated in-
creased MMP-9 in COPD compared to controls, both in
analyses of sputum [28], lung parenchyma [8] and serum
[10]. To the best of our knowledge, this is the first study,
in which serum-MMP-9 has been analysed and also
proven to be increased in a population-based COPD-
cohort. Furthermore, the association between serum
MMP-9 and impaired lung function, assessed as FEV1,
in COPD show that MMP-9 is related to disease severity
which could indicate that MMP-9 is involved in the dis-
ease process in COPD. TIMP-1 is suggested to inhibitTable 5 Multivariate analyses of factors associated with
MMP-9/TIMP-1 ratio in non-COPD and COPD, respectively
Non-COPD COPD
Beta P-value Beta P-value
Sex (female†) 0.021 0.534 −0.007 0.856
Age‡ −0.065 0.051 −0.075 0.071
Productive cough (no prc†) −0.009 0.796 0.036 0.400
Pack years‡ 0.088 0.010 0.095 0.027
FEV1% pred
‡ −0.020 0.553 −0.084 0.051
†reference value, ‡continuous variable. Significant p-values, p < 0.050, in bold.the proteolytic activity of MMPs [11,12], and the ob-
served association between overweight and TIMP-1 may
imply a protecting mechanism by overweight in COPD.
We also confirmed, as previously shown [29,30], that
serum TIMP-1 is associated with age. The MMP-9/
TIMP-1 ratio was analysed in order to evaluate the
protease-antiprotease imbalance of possible importance
in the pathogenesis of COPD and, besides increasing
pack years, decreasing FEV1% predicted was close to sig-
nificantly related to the ratio.
Chronic bronchitis is a well-known predictor of accel-
erated lung function decline and increased risk for exac-
erbations in COPD [31,32]. Also less longstanding
bronchitis symptoms, such as productive cough, seem to
be an important prognostic marker in COPD, accelerat-
ing the rate of decline in lung function [33], increasing
the risk for exacerbations [34] and mortality [33]. In a
cohort of 100 COPD-patients recruited from outpatient
care, sputum MMP-9 levels were associated with the
proportion of sputum neutrophils, independent of age,
prior smoking and presence of airflow obstruction [28].
We found a positive association between productive
cough and serum MMP-9 in COPD, indicating increased
proteolytic activity in COPD patients with bronchitis,
even though this association did not reach statistical sig-
nificance in the multivariate model. Today, COPD is
considered an inflammatory lung disease with systemic
effects which, in the western society, is caused primarily
by tobacco smoke exposure [28,35] and a population-
based study will include subjects with different clinical
manifestations or phenotypes of COPD. In the present
population-based study, the observed biomarker signals
are thus important to note, as they are clearly
hypothesis-generating for further studies. The associ-
ation between increased MMP-9 and productive cough
among subjects with COPD shown here contribute, to-
gether with previous reports from selected study popula-
tions [9,36,37], to the hypothesis that MMP-9 may be
involved in the disease process in COPD-subjects with
bronchitis symptoms and a history of frequent exacerba-
tions, or the ‘exacerbating-bronchitis’ phenotype [38].
However, in a cross-sectional study such as ours, only
associations can be evaluated and longitudinal studies
are important for the understanding of MMP-9 and
TIMP-1 in relation to measures of disease progression
and pathogenesis of different phenotypes of COPD.
Other clinical manifestations of COPD to which
MMP-9 may be of importance in the pathogenesis are
emphysema and rapid decline in lung function. It has
previously been suggested that MMP-9 is related to the
development of emphysema [39-41]. In a one-year fol-
low up of 126 patients with the more homogenous
phenotype of COPD related to alpha1-antitrypsin defi-
ciency, plasma MMP-9 was associated not only with
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transfer factor and a reduction in lung density assessed
by CT scan (computer tomography) [35]. In several stud-
ies including COPD populations with different clinical
phenotypes, MMP-9 has been related to lower lung
function [10,27,35,42] and, in our study, we have shown
that the relationship between MMP-9 and lower lung
function, assessed as FEV1% predicted, also applies to
COPD in a population-based cohort, dominated by mild
to moderate disease; GOLD stages 1–2.
Assessment of COPD disease severity is most often
based on the GOLD spirometric classification divided
into stages 1–4 [1]. Each stage includes rather wide
ranges of FEV1% predicted and, thus, the use of FEV1%
predicted, as a continuous variable, may be more sensi-
tive when it comes to evaluating biomarkers related to
disease severity. Our results illustrated this phenomenon
fairly well, as decreasing FEV1% predicted, but not
GOLD stages, was associated with MMP-9 and MMP-9/
TIMP-1 ratio among subjects with COPD. In epidemio-
logical studies identifying COPD by spirometry, the
GOLD 1 group will include a non-negligible proportion
of non-smokers without respiratory symptoms, espe-
cially among elderly [43]. Thus the GOLD 1 group may
include some “noise” that has to be taken into account
when interpreting data.
The strength of this study is the large population-
based COPD cohort identified by standardized spirom-
etry, and with a distribution of disease severity conform-
ing well to other population-based studies [9,44]. Thus,
both the internal and external validity are considered
good, and the study contributes with novel data that
imply that MMP-9 is related to disease severity and
symptoms in not only selected COPD populations but
also population-based cohorts. However, there are also
limitations of the study that merit some discussion. First,
the ELISA used to measure the levels of MMP-9 and
TIMP-1, include both total and pro-enzyme levels. Sec-
ond, it has been suggested that serum MMP-9 levels do
not reflect overall MMP-9 airway activity, as COPD is
associated with higher levels of MMP-9 but not with in-
creased MMP-9 activity. Further, the samples were
stored several years before the analyses were performed,
and it has been shown that the level of these biomarkers
decrease by time [45]. However, the geometric decrease
in measurable enzyme should be the same for all sam-
ples; half-life for degradation is identical for a single en-
zyme and the possible effects of storage are expected to
affect all samples in an equivalent manner. We can ex-
clude another potential source of error, namely the use
of different ELISA-kit-batches when performing analyses
at different time-points. Thus the measured absolute
values may be influenced by storage, but not likely the
results, regarding the observed correlations. In thepresent study, the MMP-9/TIMP-1 ratio was calculated
based on the concentrations. This way of addressing the
systemic protease-anti-protease balance has been
employed in a number of recent studies [43,46,47]. A
biologically more relevant way of estimating the pro-
teolytic balance may also include the molar MMP-9/
TIMP-1-ratio that has been used in some studies [43].
However, as only the total MMP-9 concentration was
determined here, no data on active MMP-9 are avail-
able and, hence, a relevant molar ratio cannot be calcu-
lated. This fact is a limitation of the study and analyses
of both the active and total MMP-9 concentrations and
their relation to TIMP-1 are warranted in future
studies.
Another factor to be considered is that the fixed ratio
of (FEV1/FVC <0.70) carries a risk of COPD over-
diagnosis in elderly and of under-diagnosis in younger
[43]. However, the OLIN COPD study was designed
after the shift of the millennium just after the launch of
the GOLD guidelines recommending this fixed ratio for
the definition of airway obstruction. If a similar epi-
demiological study were to be designed today, the LLN
(lower limit of normal) definition of airway obstruction
would be considered.
Conclusion
This is the first population-based cross-sectional study
analysing and demonstrating that serum MMP-9 is
higher in COPD compared with in non-COPD. Product-
ive cough and decreasing FEV1 were each associated
with MMP-9 among subjects with COPD, and decreas-
ing FEV1 remained significantly associated with MMP-9
also after adjustment for common confounders in this
population-based COPD cohort. The MMP-9/TIMP-1-
ratio may suggest an imbalance in the pulmonary
protease-antiprotease homeostasis in COPD, with a pre-
dominance of proteolytic activity that is related to im-
paired lung function and, thus, disease severity. Future
longitudinal studies are important for the further under-
standing of MMP-9 and TIMP-1 in relation to disease
progress and the pathogenesis of different COPD
phenotypes.
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